Ji, Niannian
Long, Meijun
Garcia-Vilanova, Andreu
Ault, Russell
Moliva, Juan I.
Yusoof, Kizil A.
Mukherjee, Neelam
Curiel, Tyler J.
Dixon, Hong
Torrelles, Jordi B.
Svatek, Robert S. http://orcid.org/0000-0002-0239-1338
Funding for this research was provided by:
San Antonio Medical Foundation (SAMF 2019 Fund, SAMF 2019 fund)
The Glenda and Gary Woods Foundation (Distinguished Chair in GU Oncology)
National Institutes of Health (8KL2 TR000118, K23)
The Mays Family Cancer Center at University of Texas Health San Antonio (P30 CA054174)
The Roger L. and Laura D. Zeller Charitable Foundation (Chair in Urologic Cancer)
Max and Minnie Tomerlin Voelcker Fund
Congressionally Directed Medical Research Programs (CA170270/P1P2)
Bladder Cancer Advocacy Network (2016 Young Investigator Award)
Cancer Prevention and Research Institute of Texas (RP170345)
Article History
Received: 6 December 2021
Accepted: 31 May 2022
First Online: 24 June 2022
Declarations
:
: The studies related to this manuscript were conducted abided by research ethics and approved IACUC (#20120040AR) for animal or clinical sample use (IRB protocol HSC2012-159H). All authors have consent for publishing the data from these studies. Corresponding author R.S.S. discloses other roles as Consultant for FerGene and Clinical Research Support for JBL (SWOG), FKD and Decipher Biosciences. All other authors disclose no conflict of interest.